* Anebulo Pharmaceuticals Inc ANEB.OQ reported a quarterly
adjusted loss of 8 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -10 cents. The lone analyst forecast
for the quarter was for a loss of 5 cents per share.
* Reported revenue was zero; analysts expected zero.
* Anebulo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 8 cents.
* The company reported a quarterly loss of $2.2 million.
* Anebulo Pharmaceuticals Inc shares had fallen by 14.5%
this
quarter and lost 31.8% so far this year.
FORECAST CHANGES
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Anebulo
Pharmaceuticals Inc is 6.00
This summary was machine generated from LSEG data November 14 at
04:18 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.05 -0.08 Missed
Jun. 30 2024 -0.13 -0.05 Beat
Mar. 31 2024 -0.12 -0.06 Beat
Dec. 31 2023 -0.10 -0.11 Missed